Professor Peter Rathjen interviewed by Ms Marian Heard
[nb-NO]Title[nb-NO]Professor Peter Rathjen interviewed by Ms Marian Heard
[nb-NO]Reference[nb-NO]240000105
[nb-NO]Date[nb-NO]2001
[nb-NO]Creator[nb-NO]Australian Academy of Science
[nb-NO]Scope and Content[nb-NO]Video interview and transcript of interview.
Peter Rathjen studied as an undergraduate in the Department of Biochemistry at Adelaide University, working in part as a member of the team that discovered RNA self-processing in viroids. As a 1985 Rhodes Scholar he undertook a DPhil at Oxford University, studying mobile genetic elements in yeast and mammals. He began investigating the molecular regulation of embryonic stem (ES) cell differentiation during a two-year postdoctoral position at Oxford.
He returned to the Department of Biochemistry at Adelaide University in 1990 as a lecturer. In 1995 he was promoted to the chair of this department and in 2000 he became head of the new Department of Molecular Biosciences at the University. His research interests include the molecular basis of mammalian development, the differentiation of ES cells, and the use of genetic and ES cell technologies for human therapy. His work has proven to be commercially valuable and forms a basis for the cell reprogramming division of BresaGen Ltd, an Adelaide-based biotechnology company.
Peter Rathjen studied as an undergraduate in the Department of Biochemistry at Adelaide University, working in part as a member of the team that discovered RNA self-processing in viroids. As a 1985 Rhodes Scholar he undertook a DPhil at Oxford University, studying mobile genetic elements in yeast and mammals. He began investigating the molecular regulation of embryonic stem (ES) cell differentiation during a two-year postdoctoral position at Oxford.
He returned to the Department of Biochemistry at Adelaide University in 1990 as a lecturer. In 1995 he was promoted to the chair of this department and in 2000 he became head of the new Department of Molecular Biosciences at the University. His research interests include the molecular basis of mammalian development, the differentiation of ES cells, and the use of genetic and ES cell technologies for human therapy. His work has proven to be commercially valuable and forms a basis for the cell reprogramming division of BresaGen Ltd, an Adelaide-based biotechnology company.
[nb-NO]Language[nb-NO]English
[nb-NO]External document[nb-NO]
[nb-NO]Persons keyword[nb-NO] Peter Rathjen, Marian Heard
[nb-NO]Subject[nb-NO]Biochemistry, Mammals, Genetics, Science--History, Science--Social aspects
[nb-NO]Conditions governing access[nb-NO]The Australian Academy of Science supports and encourages the use of its archive & library by making a material available to the public under Creative Commons CC BY-NC 4.0 see creativecommons.org/licenses/by-nc/4.0/
[nb-NO]Level of description[nb-NO]Item